HEMLIBRA is a medicine that is given as a shot that goes directly under the skin (a subcutaneous injection), so you don't need to find a vein to take your dose of HEMLIBRA.
"HEMLIBRA is better for me and for Carlos because it’s an injection and because of the frequency of the injections after the initial treatment."
— Maria, mom of a teenager with hemophilia A without factor VIII inhibitors, Texas
HEMLIBRA Account and Community Managers (ACMs) can provide support in both English and Spanish.
Use this handy discussion guide to get the most out of your conversation.
With the half-life of about 4 weeks, HEMLIBRA is available in your body for weeks, giving you consistent and sustained drug levels*
The term “half-life” in medicine means how long it takes for half the amount of a drug to leave the body. A longer half-life means the medicine stays in your body longer.
†Mean values depicted. Values may vary in individual patients.
Lower levels of HEMLIBRA in blood were predicted in children less than 6 months old.
*For all 3 dosing groups, the levels of HEMLIBRA were within the therapeutic range. A therapeutic range is the range of drug levels that may be expected to achieve a therapeutic treatment effect.
“Regardless of which regimen, all of the levels…are in the therapeutic range and fairly flat and even.”
— Guy Young, MD, Keck School of Medicine of the University of Southern California
For the first 4 weeks of treatment, you’ll use HEMLIBRA once a week. This will build up the levels of HEMLIBRA in your blood. After that, your doctor will help you choose a dosing schedule that’s right for you.
For more information on your HEMLIBRA dosing schedules, click here.
“You could literally go from infusing yourself to injecting yourself just twice a month.”
— Gabe, 36-year-old man with hemophilia A without factor VIII inhibitors, Texas
Gabe takes HEMLIBRA every 2 weeks, after having completed the 4 once weekly loading doses.
Please see HEMLIBRA Instructions for Use for full dosing and administration information.
Individual results may vary. Not all patients in the clinical trials had zero bleeds. See results for clinical trial patients with or without factor VIII inhibitors here.
When starting HEMLIBRA, a “loading dose” is taken once weekly for 4 weeks. After that, HEMLIBRA offers 3 regular dosing options: once weekly, once every 2 weeks, or once every 4 weeks. Talk to a doctor about dosing.
Link to Healthcare Professionals Site
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
Link to Third-Party Site
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.